No profile data available.
Akebia Therapeutics, Inc. (AKBA) is a healthcare company in the urinary system treatment drugs industry, based in Waltham, United States, with about 194 full-time employees.
It reported revenue of $236.20 million for fiscal year 2025, up 47.5% from fiscal year 2024, and net income of -$5.35 million. Its market capitalization was $221.99 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
Akebia Therapeutics reported $236.20 million in revenue for fiscal year 2025, up 47.5% from $160.18 million in fiscal year 2024.
$221.99 million as of October 9, 2026.
Listed companies of a similar size in the same industry (urinary system treatment drugs) include Travere Therapeutics, Inc. (TVTX), Vera Therapeutics, Inc. (VERA), ProKidney Corp. (PROK), Jyong Biotech Ltd. (MENS).